Movement Alert｜Innovent Biologics Falls 3.07% in Regular Trading, Pfizer Partnership Regulatory Uncertainty and Biotech Sector Selling Pressure Weigh on Shares

Market Focus

Jun 09

On June 9, Innovent Biologics fell 3.07% in regular trading, trading at 70.75 HKD/share, with trading volume of HKD 260 million. The stock has declined for multiple consecutive trading days following an 11%+ surge on May 29 when the company announced a USD 10.5 billion global strategic partnership with Pfizer.

On the news front, market concerns persist over whether the Pfizer transaction can secure required regulatory approvals. Recent speculation around potential revisions to biomedical export control lists and the U.S. COINS Act's potential restrictions on biotechnology have intensified uncertainty, continuing to suppress investor sentiment. Of the USD 10.5 billion total deal value, only the USD 650 million upfront payment is confirmed, while the remaining USD 9.85 billion in milestone payments depends on clinical, regulatory, and commercial milestones spanning 5-8 years.

Within the Biotechnology sector, broad-based weakness persists. Among individual stocks, Akeso down 3.58%, BeiGene down 1.96%, Remegen down 2.11%, SKB Bio down 0.63%, 3SBio down 1.51%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1131325825"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1131325825\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1131325825?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131325825","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Falls 3.07% in Regular Trading, Pfizer Partnership Regulatory Uncertainty and Biotech Sector Selling Pressure Weigh on Shares","media":"Market Focus","content":"<p><p>On June 9, Innovent Biologics fell 3.07% in regular trading, trading at 70.75 HKD/share, with trading volume of HKD 260 million. The stock has declined for multiple consecutive trading days following an 11%+ surge on May 29 when the company announced a USD 10.5 billion global strategic partnership with Pfizer.</p><p>On the news front, market concerns persist over whether the Pfizer transaction can secure required regulatory approvals. Recent speculation around potential revisions to biomedical export control lists and the U.S. COINS Act's potential restrictions on biotechnology have intensified uncertainty, continuing to suppress investor sentiment. Of the USD 10.5 billion total deal value, only the USD 650 million upfront payment is confirmed, while the remaining USD 9.85 billion in milestone payments depends on clinical, regulatory, and commercial milestones spanning 5-8 years.</p><p>Within the Biotechnology sector, broad-based weakness persists. Among individual stocks, Akeso down 3.58%, BeiGene down 1.96%, Remegen down 2.11%, SKB Bio down 0.63%, 3SBio down 1.51%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Falls 3.07% in Regular Trading, Pfizer Partnership Regulatory Uncertainty and Biotech Sector Selling Pressure Weigh on Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Falls 3.07% in Regular Trading, Pfizer Partnership Regulatory Uncertainty and Biotech Sector Selling Pressure Weigh on Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-09 09:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 9, Innovent Biologics fell 3.07% in regular trading, trading at 70.75 HKD/share, with trading volume of HKD 260 million. The stock has declined for multiple consecutive trading days following an 11%+ surge on May 29 when the company announced a USD 10.5 billion global strategic partnership with Pfizer.</p><p>On the news front, market concerns persist over whether the Pfizer transaction can secure required regulatory approvals. Recent speculation around potential revisions to biomedical export control lists and the U.S. COINS Act's potential restrictions on biotechnology have intensified uncertainty, continuing to suppress investor sentiment. Of the USD 10.5 billion total deal value, only the USD 650 million upfront payment is confirmed, while the remaining USD 9.85 billion in milestone payments depends on clinical, regulatory, and commercial milestones spanning 5-8 years.</p><p>Within the Biotechnology sector, broad-based weakness persists. Among individual stocks, Akeso down 3.58%, BeiGene down 1.96%, Remegen down 2.11%, SKB Bio down 0.63%, 3SBio down 1.51%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1131325825","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131325825","pubTimestamp":1780969585,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 9, Innovent Biologics fell 3.07% in regular trading, trading at 70.75 HKD/share, with trading volume of HKD 260 million. The stock has declined for multiple consecutive trading days following...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动静提示|信达生物常规交易跌3.07%辉瑞合作监管不确定性及生物科技板块抛压股价承压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On June 9, Innovent Biologics fell 3.07% in regular trading, trading at 70.75 HKD/share, with trading volume of HKD 260 million. The stock has declined for multiple consecutive trading days following an 11%+ surge on May 29 when the company announced a USD 10.5 billion global strategic partnership with Pfizer.On the news front, market concerns persist over whether the Pfizer transaction can secure required regulatory approvals. Recent speculation around potential revisions to biomedical export control lists and the U.S. COINS Act's potential restrictions on biotechnology have intensified uncertainty, continuing to suppress investor sentiment. Of the USD 10.5 billion total deal value, only the USD 650 million upfront payment is confirmed, while the remaining USD 9.85 billion in milestone payments depends on clinical, regulatory, and commercial milestones spanning 5-8 years.Within the Biotechnology sector, broad-based weakness persists. Among individual stocks, Akeso down 3.58%, BeiGene down 1.96%, Remegen down 2.11%, SKB Bio down 0.63%, 3SBio down 1.51%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}